

Prima BioMed – Fast Facts

Listings

Australian Securities Exchange (ASX), NASDAQ

Stock Codes

ASX: PRR, NASDAQ: PBMD

Issued Capital – Ordinary shares

2.07 B (approx. as of 02 Jan 2017)

Market Capitalisation

A\$74.63 M (approx. as of 02 Jan 2017)

Issued ADR's

6.3 M (approx. as of 02 Jan 2017)

Cash Position

A\$16.57 M (approx. as of 31 Dec 2016)

Board of Directors

Ms Lucy Turnbull, AO Chairman (Non-Executive)

Mr Albert Wong Deputy Chairman (Non-Executive)

Mr Marc Voigt Executive Director, Chief Executive Officer

Mr Russell J Howard, Ph.D. Non-Executive Director

Mr Pete A Meyers Non-Executive Director

Senior Management

Prof Frédéric Triebel, Ph.D. MD Chief Scientific Officer & Chief Medical Officer

Deanne Miller Chief Operating Officer

Company Overview

Prima BioMed (ASX:PRR, NASDAQ: PBMD) is a globally active biotechnology company developing novel immunotherapeutic products for cancer and autoimmune diseases.

With operations based in Australia, Germany and France, Prima BioMed is dedicated to bringing innovative treatment options to the market for patients and to maximizing value for shareholders.

Prima's core technologies are based on the **LAG-3** immune control mechanism which plays a vital role in the regulation of the T cell immune response.

Our new product **IMP761** is an agonist antibody against LAG-3 that is in preclinical development and that is supposed to switch-off specific activated immune cells in autoimmune diseases.

Our lead product **IMP321** is in clinical development for the treatment of a range of cancer indications.


IMP321 is tested in the AIPAC (**A**ctive **I**mmunotherapy **P**AClitaxel) study, a chemo-immunotherapy combination in a Phase II randomised, double-blind, placebo-controlled study in metastatic breast cancer. In the combinatorial study TACTI-mel (**T**wo **A**CTive **I**mmunotherapeutics in **mel**anoma) IMP321 is evaluated in combination with an immune checkpoint inhibitor in metastatic melanoma.

Three of our products have been partnered with large pharmaceutical partners including Eddingpharm, GSK and Novartis.

In addition, Prima's autologous dendritic cell-based product CVac™ (partnered with Neopharm) for ovarian cancer patients has entered into Sale and Licensing Agreement with Sydys Corporation to advance the CVac™ program.

Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US (ADR's).

LAG-3 / MHCII Interaction



Contact

Headquarters

Level 12, 95 Pitt Street,
Sydney, NSW 2000, Australia

enquiries@primabiomed.com.au
partnering@primabiomed.com.au

www.primabiomed.com.au

Pipeline

LAG-3 Technologies					
IMP321 (soluble LAG-3Ig)					
	Preclinical	Phase I	Phase IIa	Phase IIb	
Metastatic Breast Cancer	[Progress bar from Preclinical to Phase IIb]				WW Prima (ex China: Eddingpharm) Phase IIb trial began Oct 2015 MOA: APC activator following first-line chemotherapy leading to immunostimulation
Proof of Concept Study in Metastatic Melanoma	[Progress bar from Preclinical to Phase I]				WW Prima (ex China: Eddingpharm) Phase I trial began Jan 2016 MOA: APC activator + PD-1 checkpoint inhibitor (i.e. KEYTRUDA) leading to immunostimulation
IMP731 (depleting LAG-3 mAb)					
Autoimmune Diseases	[Progress bar from Preclinical to Phase I]				WW GSK Phase I trial began Jan 2015 MOA: LAG-3 depleting antibody leading to immunosuppression
IMP701 (antagonist LAG-3 mAb)					
Cancer	[Progress bar from Preclinical to Phase I]				WW Novartis Phase I trial began Aug 2015 MOA: LAG-3 antagonist antibody leading to immunostimulation
IMP761 (agonist LAG-3 mAb)					
Autoimmune Diseases	[Progress bar from Preclinical to Phase I]				WW Prima MOA: LAG-3 agonist antibody leading to immunosuppression
Autologous Dendritic Cell Therapy					
CVac™					
Ovarian Cancer	[Progress bar from Preclinical to Phase IIa]				WW Sydys Corporation (ex Israel: Neopharm) Phase IIb completed (CAN-003)


New product candidate: IMP761

IMP761 is a humanized monoclonal antibody binding to LAG-3+ autoreactive T-cells as an agonist in order to reduce immune reactions in autoimmune diseases.



Lead Target: LAG-3

Targeting of LAG-3 leads to multiple therapeutics in numerous indications



IMP321 is a recombinant protein consisting of a dimer of LAG-3 that has been engineered to be soluble rather than expressed on the surface of cells.

IMP321 works as an **immune stimulator** as it is a first-in-class antigen presenting cell (APC) activator to induce sustained immune cell responses. This application is promising in immuno-oncology therapies and as therapies against viral infections.

In order to reduce immune cell responses, the binding of an agonist mAb like IMP761 or a depleting mAb like IMP731 to LAG-3 on activated autoreactive T-cells can be a promising **immunosuppression** therapy in autoimmune diseases.

For detailed information about the mode of action please have look at the video on our website and at the link below.

<https://www.youtube.com/embed/MKAdIMc25uc>

Lead Technology: LAG-3 (Lymphocyte Activation Gene-3 / LAG-3 or CD223)

LAG-3 is involved in the regulation of T cells. It has a dual mechanism of action and controls the signaling between T cells and antigen presenting cells (APC's).

Forward looking statements: Any forward looking statements in this fact sheet have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed Ltd.'s control.